Biomarker analyses in CLEOPATRA: A phase Ill, placebo-controlled study of pertuzumab in HER2-positive, first -line metastatic breast cancer (MBC)

Category Primary study
JournalCANCER RESEARCH
Year 2012
This article has no abstract
Epistemonikos ID: ebcda0dfe448fdf7f70eb8364729a743d74c8414
First added on: Feb 05, 2025